Aclaris Therapeutics (ACRS) Tops Q1 EPS by 9c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.31), $0.09 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Goldman Sachs Starts Chagee Holdings (CHA) at Neutral
• Jefferies Downgrades Belimo Holding AG (BEAN:SW) (BLHWF) to Hold